Harbour BioMed's HBM7004 Receives NMPA Acceptance for Advanced Solid Tumors Treatment

In a significant advancement for cancer therapy, Harbour BioMed, a global biopharmaceutical company focusing on innovative antibody therapeutics, has announced the acceptance of its Investigational New Drug (IND) application for HBM7004 by China's National Medical Products Administration (NMPA). This acceptance comes shortly after the drug received clearance from the U.S. Food and Drug Administration (FDA), highlighting its potential as a pivotal treatment for advanced solid tumors.

A Step Forward in Immunotherapy

HBM7004 represents a groundbreaking approach in the realm of cancer immunotherapy. It is a bispecific antibody developed through Harbour BioMed's proprietary HBICE® technology platform. This innovative drug works by targeting specific pathways in the immune system, particularly focusing on the B7H4 protein, which is often overexpressed in various cancers. By activating T cells directly within the tumor environment, HBM7004 aims to enhance anti-tumor responses while minimizing adverse effects associated with systemic therapies.

Preclinical studies have shown promising results, demonstrating the ability of HBM7004 to activate T cells in a manner dependent on B7H4, leading to robust anti-tumor efficacy in several animal models. The studies also indicated a noteworthy improvement in the drug's stability in vivo, alongside reduced systemic toxicity compared to traditional therapies. Such findings are critical as they suggest a potentially safer and more effective treatment option for patients whose tumors have not responded to existing therapies.

Synergistic Potential and Future Directions

Another exciting aspect of HBM7004 is its demonstrated synergistic effect when used in combination with another bispecific antibody targeting 4-1BB. This combination therapy showed strong potential even at low effector-to-target cell ratios, opening doors to explore personalized treatment regimens that could offer enhanced efficacy without compromising safety.

Dr. Jingsong Wang, the Founder, Chairman, and Chief Executive Officer of Harbour BioMed, expressed enthusiasm regarding the NMPA's acceptance, stating that it exemplifies the company's strategy of leveraging proprietary technology to develop next-generation immunotherapies. With the backing of encouraging preclinical data, Harbour BioMed is committed to collaborating with regulatory authorities in advancing HBM7004 through clinical evaluation phases in China.

About Harbour BioMed

Harbour BioMed is not just making waves with HBM7004; the company is dedicated to discovering and developing a portfolio of novel antibody therapeutics across various fields, including oncology and immunology. Their proprietary platforms, such as Harbour Mice® for generating fully human monoclonal antibodies and the advanced HBICE® bispecific antibody technology, equip them with exceptional capabilities to address significant medical needs effectively.

By also integrating cutting-edge AI technologies like their Hu-mAtrIxTM platform, Harbour BioMed is strategically positioned to expedite the development of innovative therapies, exemplifying their commitment to reshaping the future of medicine.

This acceptance by the NMPA marks a milestone for Harbour BioMed and underscores the growing importance of innovative treatments in oncology, paving the way for future breakthroughs in cancer therapy. With HBM7004 on the horizon, patients suffering from advanced solid tumors may soon have access to a novel approach that offers hope where traditional therapies have faltered.